Eikon steps down into Nasdaq
With a slashed valuation the newly listed biotech heads for phase 3.
Neok plays a high-risk bispecific conjugate game
Armed with $75m the company takes a risky asset into the clinic.
One Genmab Rybrevant challenge is rendered moot
GEN1286 looks dead, though MCLA-129 continues for now.
AstraZeneca goes all-in on AbelZeta’s Car
A fresh licensing deal tidies up years of work between the two companies.
Reality hits Nuvation
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Eikon tries to follow Aktis
After Aktis's $318m flotation Eikon is a bigger proposition.
AbbVie is next to the VEGF bispecific table
$650m buys the group rights to RemeGen’s RC148.
